Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.04, Zacks reports. During the same quarter in the previous year, the company posted ($0.13) earnings per share.
Nautilus Biotechnology Stock Down 4.3 %
Shares of NAUT stock traded down $0.12 during mid-day trading on Wednesday, reaching $2.65. The company’s stock had a trading volume of 43,413 shares, compared to its average volume of 74,739. The company’s 50 day simple moving average is $2.75 and its 200-day simple moving average is $2.62. Nautilus Biotechnology has a 12-month low of $2.19 and a 12-month high of $3.45. The firm has a market capitalization of $332.34 million, a PE ratio of -4.73 and a beta of 1.22.
Insider Activity
In related news, VP Mary E. Godwin sold 35,000 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $2.85, for a total transaction of $99,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 40.50% of the company’s stock.
Nautilus Biotechnology Company Profile
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
Read More
- Five stocks we like better than Nautilus Biotechnology
- Overbought Stocks Explained: Should You Trade Them?
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Compound Interest and Why It Matters When Investing
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- 3 Warren Buffett Stocks to Buy Now
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.